

-2-

91
one product selected from the group consisting of TCR β , CD3, CD4, and CD8 the percentage of tumor cells of each of the samples which express said at least one product, wherein the tumor is predicted to have substantially no metastatic potential when no tumor cells in all of the samples are detected to express said at least one product.

[Please add the following claim:

2. A method of predicting the lymphotropic metastatic potential of a primary human colon tumor, the method comprising obtaining a plurality of representative samples of the tumor and determining for at least one product selected from the group consisting of TCR β , CD4, and ZAP-70 the percentage of tumor cells of each of the samples which express said at least one product, wherein the tumor is predicted to have substantially no metastatic potential when no tumor cells in all of the samples are detected to express said at least one product.

REMARKS

Attached hereto is a marked-up version of the changes made to the specification by the current Amendment. The attached page is captioned "Version with Markings to Show Changes Made."

This Amendment is being filed as a submission with a Request for Continued Examination (RCE) filed after payment of the issue fee, Submittal of Formal drawings, and Letter re correction of Title, all of which papers were mailed to the Patent Office with a Certificate of Mailing on June 26, 2002. Enclosed is a copy of the postcard receipt. The patent had not issued as of February 26, 2003. On that date a Status Request was mailed to the Patent Office. Enclosed is a copy of the postcard receipt therefor. Applicant still has not heard anything from the Patent Office regarding the status of this application. A check today of the